Experimental study on the treatment of intracerebral glioma xenograft with human cytokine-induced killer cells

Cellular Immunology

Volumn 253, Issue 1-2, 2008, Pages 59-65

  Wang, Peng ^a   Yu, Jin pu ^a   Gao, Song yuan ^a   An, Xiu mei ^a   Ren, Xiu bao ^a   Wang, Xiao guang ^a   Li, Wen liang ^a  

^a KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

Cell mediated immunity; Cytokine induced killer cells; Glioma; U251 cells; U87 cells

Indexed keywords

CYTOKINE; LYMPHOKINE;

ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KILLER CELL; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TUMOR GROWTH; XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CELL PROLIFERATION; CYTOKINES; GLIOMA; HUMANS; KILLER CELLS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHENOTYPE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

MUS MUSCULUS;

EID: 51449090688     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2008.04.014     Document Type: Article

References (22)

1. Salford L.G., Brun A., and Nirfalk S. Ten-year survival among patients with supratentorial astrocytomas grade III and IV. J. Neurosurg. 69 (1988) 506-509
2. Schmidt-Wolf G.D., Negrin R.S., and Schmidt-Wolf I.G. Activated T cells and cytokine-induced CD3+CD56+ killer cells. Ann. Hematol. 74 (1997) 51-56
3. Schmidt-Wolf I.G., Lefterova P., Johnston V., et al. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell. Immunol. 169 (1996) 85-90
4. Schmidt-Wolf I.G., Finke S., Trojaneck B., et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br. J. Cancer 81 (1999) 1009-1016
5. Verneris M.R., Kornacker M., Mailander V., et al. Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis. Cancer Immunol. Immunother. 49 (2000) 335-345
6. Scheffold C., Brandt K., Johnston V., et al. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. Bone Marrow Transplant. 15 (1995) 33-39
7. Verneris M.R., Arshi A., Edinger M., et al. Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. Clin. Cancer Res. 11 (2005) 4561-4570
8. Ren X., Yu J., Liu H., et al. Th1 bias in PBMC induced by multicycles of auto-CIKs infusion in malignant solid tumor patients. Cancer Biother. Radiopharm. 21 (2006) 22-33
9. Li H., Yu J.P., Cao S., et al. CD4+CD25+ regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients. J. Clin. Immunol. 27 (2007) 317-326
10. Lu P.H., and Negrin R.S. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J. Immunol. 153 (1994) 1687-1696
11. Hoyle C., Bangs C.D., Chang P., et al. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 92 (1998) 3318-3327
12. Mehta B.A., Schmidt-Wolf I.G., Weissman I.L., et al. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. Blood 86 (1995) 3493-3499
13. Gritzapis A.D., Dimitroulopoulos D., Paraskevas E., et al. Large-scale expansion of CD3(+)CD56(+) lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants. Cancer Immunol. Immunother. 51 (2002) 440-448
14. Hoffman D.M., Gitlitz B.J., Belldegrun A., et al. Adoptive cellular therapy. Semin. Oncol. 27 (2000) 221-233
15. Jacobs S.K., Wilson D.J., Kornblith P.L., et al. In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes. J. Neurosurg. 64 (1986) 114-117
16. Hayes R.L., Koslow M., Hiesiger E.M., et al. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 76 (1995) 840-852
17. Dillman R.O., Duma C.M., Schiltz P.M., et al. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J. Immunother. 27 (2004) 398-404
18. Holladay F.P., Heitz T., and Wood G.W. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells. J. Neurosurg. 77 (1992) 757-762
19. Prins R.M., Graf M.R., Merchant R.E., et al. Cytotoxic T cells infiltrating a glioma express an aberrant phenotype that is associated with decreased function and apoptosis. Cancer Immunol. Immunother. 50 (2001) 285-292
20. Jaworski D.M., Kelly G.M., Piepmeier J.M., et al. BEHAB (brain enriched hyaluronan binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines. Cancer Res. 56 (1996) 2293-2298
21. Bock N.A., Nieman B.J., Bishop J.B., et al. In vivo multiple-mouse MRI at 7 Tesla. Magn. Reson. Med. 54 (2005) 1311-1316
22. Nieman B.J., Bock N.A., Bishop J., et al. Fast spin-echo for multiple mouse magnetic resonance phenotyping. Magn. Reson. Med. 54 (2005) 532-537